MErCuRIC was featured as a Horizon 2020 Success Story on the European Commission’s Policies, information and services webpage on April 14, 2018. Below is an excerpt from the story.
“Made-to-measure treatments are becoming possible because of the growing understanding of the genetic and molecular nature of cancers and disease in general,” says Coordinator Sandra Van Schaeybroeck of Queen’s University Belfast. As well as offering welcome benefits to future colorectal cancer sufferers, MErCuRIC is an example of where medical treatment is heading.
“MERCURIC focuses on a particular sub-group of CRC patients. However, this ‘stratified’ approach beginning with a genetic and molecular profile of a patient can, and is, increasingly applied to many cancers and other disease groups.”
Read the entire story here.